Frédéric Tangy, PhD, Dr.Sci.
Director of research DR1 CNRS
Head of Viral Genomics and Vaccination Unit, Institut Pasteur, Paris
Viral Genomics and Vaccination Unit
INSTITUT PASTEUR
28 rue du Dr Roux, 75015 Paris, France
Tel: (33) 1 45 68 87 70
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Frédéric Tangy, PhD, Dr.Sc., Director of Research (DR1) at CNRS, is the head of the Viral Genomics and Vaccination Research Unit at Institut Pasteur, Paris (CNRS UMR-3569). He is director of the international Vaccinology course of Institut Pasteur, former VP of the Scientific Council of Institut Pasteur, and member of the Assembly of Institut Pasteur. He is the author of 130 scientific publications and 22 patents. His main research program is dedicated to the generation of polyvalent recombinant vaccines based on a viral vector derived from measles attenuated vaccine. This project extends from the design of antigens and generation of recombinant vectors, to preclinical and clinical development in the fields of HIV, dengue, Zika, Ebola and others. A measles-chikungunya vaccine recently tested in clinical trial was proven safe and immunogenic in adults with preexisting measles immunity and is currently tested in a large phase II trial. Similarly he explores the anticancer capacity of modified measles vaccine. A clinical trial in ovarian cancer is in preparation. His fundamental research concerns the study of host innate immune responses to viral infections. In particular, he investigates virus-host protein interactions using functional genomic and proteomic approaches such as yeast two-hybrid, mass spectrometry, next generation sequencing and high-throughput drug screening. This project leads to identifying determinants of pathogenicity/attenuation and new drug targets. In 2004 he cofounded the company Epixis. Recently in 2015, he created the company Oncovita dedicated to cancer treatment using modified measles virus.